secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2026-09-24T21:11:07+00:00
Accession:  0001193125-26-401157
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Phase 2 RADIANT: remlifanserin 60mg misses primary endpoint (p=0.0603) but supports Phase 3
--------------------------------------------------------------------------------

- Primary SAPS-H+D: 60mg change -12.6 vs placebo -10.4 (week 6), effect size 0.26, p=0.0603.
- Key secondary CGI-S-ADP: 60mg change -1.3 vs -0.9, effect size 0.37, p=0.0077 (nominal).
- 30mg dose minimal improvement; company to amend Phase 3 to remove 30mg arm.
- Safety favorable: no QT signal, no deaths, no motor/cognition negative impact; AE rates similar to placebo.
- Plan to continue Phase 3; detailed results at CTAD Nov 16-19, 2026 in Boston.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526401157/0001193125-26-401157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526401157/d168737d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-401157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer